JO
VKTX icon

John Overdeck’s Viking Therapeutics VKTX Stock Holding History

John Overdeck’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154M Sell
3,937,414
-494,728
-11% -$16M 0.11% 206
2026
Q1 		$144M Buy
4,432,142
+1,996,405
+82% +$64.2M 0.12% 199
2025
Q4 		$85.7M Buy
2,435,737
+350,250
+17% +$12.4M 0.12% 212
2025
Q3 		$54.8M Buy
2,085,487
+771,704
+59% +$23M 0.08% 300
2025
Q2 		$34.8M Buy
1,313,783
+1,261,369
+2,407% +$33.2M 0.06% 376
2025
Q1 		$1.27M Buy
+52,414
New +$1.66M ﹤0.01% 2039
2024
Q4 		– Sell
-51,546
Closed -$3.26M – 3509
2024
Q3 		$3.26M Sell
51,546
-2,136
-4% -$125K 0.01% 1339
2024
Q2 		$2.85M Sell
53,682
-7,164
-12% -$470K 0.01% 1315
2024
Q1 		$4.99M Sell
60,846
-58,100
-49% -$2.59M 0.01% 972
2023
Q4 		$2.21M Sell
118,946
-499,244
-81% -$6.53M 0.01% 1454
2023
Q3 		$6.84M Buy
618,190
+199,016
+47% +$2.85M 0.02% 760
2023
Q2 		$6.79M Sell
419,174
-276,531
-40% -$5.79M 0.02% 806
2023
Q1 		$11.6M Sell
695,705
-569,483
-45% -$5.88M 0.03% 539
2022
Q4 		$11.9M Buy
1,265,188
+278,865
+28% +$1.24M 0.04% 500
2022
Q3 		$2.68M Sell
986,323
-55,679
-5% -$182K 0.01% 1014
2022
Q2 		$3.01M Sell
1,042,002
-202,090
-16% -$500K 0.01% 984
2022
Q1 		$3.73M Buy
1,244,092
+310,611
+33% +$1.11M 0.01% 1062
2021
Q4 		$4.29M Buy
933,481
+57,157
+7% +$320K 0.01% 1287
2021
Q3 		$5.5M Buy
876,324
+48,380
+6% +$299K 0.01% 1163
2021
Q2 		$4.96M Sell
827,944
-294,887
-26% -$1.75M 0.01% 1212
2021
Q1 		$7.1M Buy
1,122,831
+832,611
+287% +$5.86M 0.02% 867
2020
Q4 		$1.63M Buy
290,220
+225,596
+349% +$1.37M ﹤0.01% 1623
2020
Q3 		$376K Sell
64,624
-397,276
-86% -$2.74M ﹤0.01% 2442
2020
Q2 		$3.33M Buy
+461,900
New +$3.07M 0.02% 843
2019
Q1 		– Sell
-389,620
Closed -$2.98M – 3502
2018
Q4 		$2.98M Buy
+389,620
New +$4.66M 0.01% 1042

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

John Overdeck's VKTX Position: Q2 2026 in Review

John Overdeck reduced its Viking Therapeutics (VKTX) stake by 11% in Q2 2026, selling an estimated $16M and leaving 3,937,414 shares worth $154M. The position accounts for 0.11% of the portfolio, ranked #206.

John Overdeck first reported a position in VKTX in Q4 2018 and has held it in 25 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • John Overdeck held 3,937,414 shares of Viking Therapeutics worth $154M as of Q2 2026.
  • John Overdeck sold 494,728 Viking Therapeutics shares in Q2 2026, an estimated $16M.
  • Viking Therapeutics made up 0.11% of John Overdeck's portfolio in Q2 2026, its #206 holding.
  • John Overdeck first reported a position in Viking Therapeutics in Q4 2018 and has held it in 25 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.